摘要
药物涂层支架的引入减少了支架内再狭窄的风险,同时增宽了经皮冠状动脉介入治疗的适应证。然而,它能够诱导超敏反应,干扰内皮化和血管愈合的过程而导致晚期永久性支架持续性或获得性支架膨胀不良,而延迟内皮化和支架的膨胀不良可能导致晚期和极晚期支架内血栓的形成。生物可降解支架的出现克服了这些限制,提供短暂的支撑后逐渐消失。该文就目前生物可降解镁合金支架研究的新进展、其临床应用及未来的前景予以综述。
The introduction of metallic drug-eluting stents has reduced the risk of restenosis and widened the indications of percutaneous coronary intervention in treatment of coronary artery disease. However,this medical device can induce hypersensitive reaction that interferes with the endothelialization and healing process resulting in late persistent or acquired malapposition of the permanent metallic implant. Delayed endotheliaization and malapposition may lead to late and very late stent thrombosis. Bioresorbable scaffolds（ BRS） have been introduced to potentially overcome these limitations,as they provide temporary scaffolding and then disappear. Here is to make a review of the new developments in magnesium BRS technology,to describe its clinical application and to discuss the future prospects of this innovative therapy.
出处
《医学综述》
2015年第6期981-983,共3页
Medical Recapitulate
基金
国家自然科学基金(81271676)
关键词
镁合金支架
可降解
冠状动脉支架
再狭窄
Magnesium alloy stents
Bioresorbable
Drug-eluting stent
Restenosis
